首页> 外国专利> oral or topical composition and use of a factor 2-related erythroid nuclear factor 2 agonist and a hepatic receptor x agonist as active agents in an oral or topical composition to benefit hair fiber growth and / or induce the antioxidant response element (are)

oral or topical composition and use of a factor 2-related erythroid nuclear factor 2 agonist and a hepatic receptor x agonist as active agents in an oral or topical composition to benefit hair fiber growth and / or induce the antioxidant response element (are)

机译：口服或局部用组合物以及使用因子2相关的类红细胞核因子2激动剂和肝受体x激动剂作为口服或局部用组合物中的活性剂以有益于毛发生长和/或诱导抗氧化反应成分的方法

页面导航

摘要
著录项
相似文献

摘要

An oral or topical composition comprising a factor 2 related erythroid nuclear factor 2 agonist and a hepatic receptor x agonist is disclosed, wherein the amounts of each of the factor 2 related erythroid nuclear factor 2 agonist and the receptor agonist are each. hepatic x produce a synergistic benefit of hair fiber growth, wherein the oral or topical composition comprises = 9, preferably = 8% by weight of beta-sitosterol, wherein when the oral or topical composition comprises a catechin, the oral or The topical composition comprises 0.001 to 90, preferably 0.005 to 70, more preferably 0.01 to 50% by weight of catechins, wherein the oral or topical composition excludes pregnenolone, 4,5-dihydrofuranodien-6-one, epoxy santamarine, hydroquinone, longistiline. , monacoline k, protoanemonine, n- (2,2,2-trifluorethyl) -N- [4- (2,2,2-trifluor-1-hydroxy-1-trifluoromethyl ethyl) phenyl] - benzenesulfonamide, dihydronepetalactone, iridomirmecin and dihydroacti nidiolide, wherein when the oral or topical composition comprises gugulsterone and epigallocatechin gallate, the oral or topical composition excludes a weight ratio of gugulsterone to epigalocatechin gallate from 1 to 28, and wherein when the oral or topical composition comprises dilauramide glutamide sodium lysine, the oral or topical composition excludes 0.3% by weight of dilauramide glutamide sodium lysine.

机译：公开了包含因子2相关的类红细胞核因子2激动剂和肝受体x激动剂的口服或局部组合物，其中因子2相关的类红细胞核因子2激动剂和受体激动剂各自的量分别是。肝x产生头发纤维生长的协同益处，其中口服或局部用组合物包含按重量计＝ 9，优选＝ 8％的β-谷固醇，其中当口服或局部用组合物包含儿茶素时，口服或局部用组合物包含0.001-90，优选0.005-70，更优选0.01-50重量％的儿茶素，其中口服或局部用组合物不包括孕烯醇酮，4，5-二氢呋喃二烯-6-酮，环氧三聚体，氢醌，longistiline。，莫纳可林k，原鸟氨酸，n-（2,2,2-三氟乙基）-N- [4-（2,2,2-三氟-1-羟基-1-三氟甲基乙基）苯基]-苯磺酰胺，二氢荆芥内酯，伊立多菌素和二氢acti nidiolide，其中当口服或局部用组合物包含古格列酮和表没食子儿茶素没食子酸酯时，口服或局部用组合物排除古格列酮与表没食子儿茶素没食子酸酯的重量比为1至28，并且其中当口服或局部用组合物包含二月桂酰胺谷氨酰胺赖氨酸钠时口服或局部用组合物不包括按重量计0.3％的二月桂酰胺谷氨酰胺赖氨酸钠。

著录项

公开/公告号BR112017012648A2

专利类型
公开/公告日2017-12-26

原文格式PDF
申请/专利权人 UNILEVER N.V.;
展开▼

申请/专利号BR20171112648
发明设计人 GAIL JENKINS;LINDA JANE WAINWRIGHT;MAGDALENA SAWICKA;RANJIT KAUR BHOGAL;
展开▼

申请日2015-12-04
分类号A61K31/56;A61K8/49;A61K8/63;A61K8/97;A61K31/575;A61K36/04;A61K36/15;A61K36/185;A61K36/324;A61K36/328;A61K36/68;A61K36/73;A61K36/88;A61Q17;
国家 BR
入库时间 2022-08-21 12:53:47

相似文献

专利
外文文献